| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.33) by...
																	
																	INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces the submission of a manu...
																	INmune Bio Inc. (NASDAQ:INMB) ("INmune" or "the Company"), a clinical-stage inflammation and immunology company...
																	INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by...
																	
																	
																	
																	https://www.businessinsider.com/short-squeeze-stock-market-meme-stocks-retail-investors-25-8